<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/45BA7E10-0932-4602-BDB0-8E43A4E53B39"><gtr:id>45BA7E10-0932-4602-BDB0-8E43A4E53B39</gtr:id><gtr:name>Mina Alpha Limited</gtr:name><gtr:address><gtr:line1>Translation &amp; Innovation Hub, 80 Wood Lane</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>W12 0BZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/45BA7E10-0932-4602-BDB0-8E43A4E53B39" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>45BA7E10-0932-4602-BDB0-8E43A4E53B39</gtr:id><gtr:name>Mina Alpha Limited</gtr:name><gtr:address><gtr:line1>Translation &amp; Innovation Hub, 80 Wood Lane</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>W12 0BZ</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>217844.0</gtr:offerGrant><gtr:projectCost>311206.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/66C893A6-75F6-4C83-94F8-AC9D28029660" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>66C893A6-75F6-4C83-94F8-AC9D28029660</gtr:id><gtr:name>Link Technologies Limited</gtr:name><gtr:address><gtr:line1>3, Mallard Way, Strathclyde Business Park</gtr:line1><gtr:city>Bellshill</gtr:city><gtr:postCode>ML4 3BF</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>190012.0</gtr:offerGrant><gtr:projectCost>271446.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C705C809-8823-4B6E-86A9-BA639C831D5E"><gtr:id>C705C809-8823-4B6E-86A9-BA639C831D5E</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Blakey</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=103855"><gtr:id>BB2D0623-FDDA-4E05-89AF-52FA407B06F5</gtr:id><gtr:title>Development of liver targeted gene activation for liver disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>103855</gtr:grantReference><gtr:abstractText>The project is developing an innovative drug for advanced liver disease including non-alcoholic steatohepatitis (NASH) where there are limited existing treatment options. The drug is designed to be administered subcutaneously, selectively target to the liver and increase the expression of a protein in the liver which is down-regulated in disease. Increasing expression of the target protein should both improve the function of normal liver cells impacted by the disease and inhibit the disease itself and thus restore normal liver function. The outcome of the proposed work, if successful, will be a clinical candidate that can be progressed to testing in liver diseases such as NASH as well as a selective delivery platform that can be used with chemically related drugs to treat a range of liver diseases.</gtr:abstractText><gtr:fund><gtr:end>2019-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>407856</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">103855</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>